Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

yttrium Y 90 monoclonal antibody Lym-1

Known as: yttrium Y 90 MOAB Lym-1, monoclonal antibody Lym-1, yttrium Y 90, MOAB Lym-1, yttrium Y 90 
A radioimmunoconjugate of a murine monoclonal antibody, MoAb Lym-1, labeled with yttrium 90 (Y-90). MoAb Lym-1 recognizes an epitope of the… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Background: About one-third of patients with relapsed B-cell malignancies develop human anti-mouse antibody (HAMA) following… Expand
  • table 1
  • table 2
  • table 3
  • figure 2
  • figure 1
2000
2000
Radioimmunotherapy using radiolabeled monoclonal antibodies against tumor-associated antigens has been efficacious, particularly… Expand
Highly Cited
1999
Highly Cited
1999
Antilymphoma mouse monoclonal antibody (MoAb) Lym-1, labeled with 67Cu or 131I, has demonstrated promising results in… Expand
Highly Cited
1998
Highly Cited
1998
PURPOSE This trial was conducted to assess the toxicity and efficacy of 131I-Lym-1 in patients with either malignant B-cell non… Expand
Highly Cited
1998
Highly Cited
1998
PURPOSE Lym-1, a monoclonal antibody (MoAb) that preferentially targets malignant lymphocytes, has induced therapeutic responses… Expand
Highly Cited
1997
Highly Cited
1997
Because most patients with advanced non‐Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) respond to… Expand
1996
1996
UNLABELLED Metallic radioimmunoconjugates have promise for radioimmunoimaging and therapy. Macrocyclic chelating agents allow… Expand
Highly Cited
1996
Highly Cited
1996
A murine antihuman B-cell monoclonal antibody, Lym-1, has shown considerable promise for the treatment of human malignant… Expand
Highly Cited
1994
Highly Cited
1994
Background. Although chronic lymphocytic leukemia is usually indolent and responsive to treatment early in its course, later… Expand
Highly Cited
1990
Highly Cited
1990
Eighteen patients with Stage 4 B-cell malignancies, which were primarily of intermediate or high grade and progressive despite… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4